30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

2Q13 Revenue: Bacterin

$8.3MM, +1%

  • Growth attributed to higher volume sales, partially offset by lower sales prices due to discounting for higher-volume distributors/preferred vendors
  • Able to win back previous accounts, stabilize core hospital business
  • Received clearance for additional indication for OsteoSelect DBM Putty for spinal fusion
  • Not currently working with any physician-owned distributors, not anticipating doing so in the future